Qualified Clinical Data Registry

Quality reporting flexibility and MACRA readiness

Philips Wellcentive’s recognition by the Centers for Medicare & Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) brings broad quality reporting benefits across multiple payer programs.

Utilizing a QCDR for reporting allows practices to:

  • Avoid PQRS payment adjustments
  • Align reporting to multiple payers
  • Submit quality measures beyond specific Medicare programs
  • Report via the QCDR instead of through GPRO based on practice size
  • Gain access to Philips Wellcentive’s measures library toward expanded and strategic quality reporting

In terms of measure types, practices can utilize QCDR reporting from the following measures categories, and select non-PQRS measures:

Specialized registry benefits

In addition, our QCDR recognition allows operation as a specialized registry within meaningful use, MSSP ACO and upcoming MACRA reporting.

Preparing for MACRA

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is scheduled to begin in 2019 as the go-forward mechanism for broad CMS quality reporting.

MACRA features two reporting and payment tracks:

  • Merit-based Incentive Payment System (MIPS)
    • MIPS has four reporting elements within it
      • Quality, which bundles PQRS and the Value-based Modifier
      • Meaningful Use
      • Clinical Practice Improvements
      • Resource Use
  • Alternative Payment Models (APM)
    • ACO, PCMH and other demonstration projects

As MACRA aligns quality reporting programs, submission and the ability for more frequent performance tracking, QCDRs provide a vehicle for strategic and streamlined workflows and reimbursement capture.

CMS maintains a list of credited QCDRs, which can be accessed here.

“We determined as an organization that reporting on oncology measures alone would do little to improve the care we deliver our patients. We serve our patients best when we remain ahead of government requirements for quality. By focusing on preventive measures—which have real relevance to cancer outcomes—our clinicians consider the whole patient, not just a portion of their care and not just the disease.”
Leslie Botnick, M.D
Leslie Botnick, M.D.Co-Founder and CMO, Vantage Oncology.
Additional resources

Philips Wellcentive advocates for providers and healthcare stakeholders on matters of public policy through public comment letters and interaction with government entities.

Key capabilities



Aggregate and normalize data from multiple clinical and claims systems



Provide actionable insight for any PHM or VBR program



Proactively improve clinical outcomes and optimize utilization



Submit data and outcomes directly to CMS and Commercial Payers